Asieris Signs a Worldwide Development and Commercialization Agreement with Photocure for Cevira

 Asieris Signs a Worldwide Development and Commercialization Agreement with Photocure for Cevira

Asieris Signs a Worldwide Development and Commercialization Agreement with Photocure for Cevira

Shots:

  • Photocure to receive $5M upfront within 6mos. after signing the agreement and $14M on the approval of the second indication in the US, China & EU with royalties on sales. Photocure will also receive $18M & $36M as a regulatory & clinical milestone in China & the US and EU respectively
  • The companies collaborated to develop & commercialize Cevira for the treatment of HPV induced cervical precancerous lesions. Asieris will be responsible for the manufacturing of the Cevira and Photocure will responsible for the manufacturing of API
  • Cevira is photo-dynamic drug-device combination therapy, being developed for non-surgical treatment of cervical dysplasia, placed on the cervix by the gynecologist with no disruption in normal activities

Click here to read full press release/ article | Ref: PRNewsWire | Image: Photocure

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post